{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-23-003210","form_type":"8-K","ticker":"SBFM","cik":"0001402328","company_name":"Sunshine Biopharma Inc.","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.712495+00:00","generated_at":"2026-06-15T03:52:12.605760+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Sunshine Biopharma reports Q1 2023 revenues of $4.89M, up 2,100% YoY","bullets":["Gross revenues of $4,894,053 for Q1 2023, a 2,100% increase over Q1 2022, driven by Nora Pharma acquisition.","Repurchased 445,711 common shares under $2M stock buyback program; shares cancelled, reducing outstanding count to 22,139,921.","Entered research agreement with Jewish General Hospital to advance Adva-27a anticancer compound through IND-enabling studies.","Obtained exclusive worldwide license from University of Arizona for PLpro protease inhibitors of SARS-CoV-2 (COVID-19)."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-23-003210","json":"https://secwatch.observer/filing/0001683168-23-003210.json","markdown":"https://secwatch.observer/filing/0001683168-23-003210.md","text":"https://secwatch.observer/filing/0001683168-23-003210.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1402328/000168316823003210/0001683168-23-003210-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1402328/000168316823003210/sunshine_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T03:52:12.605760+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}